DE69936948D1 - Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten - Google Patents

Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Info

Publication number
DE69936948D1
DE69936948D1 DE69936948T DE69936948T DE69936948D1 DE 69936948 D1 DE69936948 D1 DE 69936948D1 DE 69936948 T DE69936948 T DE 69936948T DE 69936948 T DE69936948 T DE 69936948T DE 69936948 D1 DE69936948 D1 DE 69936948D1
Authority
DE
Germany
Prior art keywords
virus
concentration
methods
containing compositions
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936948T
Other languages
English (en)
Other versions
DE69936948T2 (de
Inventor
Andreas Frei
Henry Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Laureano L Bondoc Jr
Frederick William Porter
John Chu-Tay Tang
Peter Ihnat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69936948D1 publication Critical patent/DE69936948D1/de
Application granted granted Critical
Publication of DE69936948T2 publication Critical patent/DE69936948T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
DE69936948T 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten Expired - Lifetime DE69936948T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US24462 1998-02-17
US7964398A 1998-05-15 1998-05-15
US79643 1998-05-15

Publications (2)

Publication Number Publication Date
DE69936948D1 true DE69936948D1 (de) 2007-10-04
DE69936948T2 DE69936948T2 (de) 2008-05-15

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69936948T Expired - Lifetime DE69936948T2 (de) 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69942708T Expired - Lifetime DE69942708D1 (de) 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69942708T Expired - Lifetime DE69942708D1 (de) 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Country Status (25)

Country Link
EP (4) EP1054955B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100918187B1 (de)
CN (2) CN100374551C (de)
AR (3) AR020054A1 (de)
AT (3) ATE341614T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2320419C (de)
CO (1) CO4820440A1 (de)
DE (3) DE69936948T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2272053T3 (de)
HK (3) HK1028416A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CN1244215B (zh) 1996-11-20 2010-11-03 荷兰克鲁塞尔公司 改进的腺病毒载体生产和纯化方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE69940354D1 (de) * 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP2420247A1 (de) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus-Formulierungen
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
JP2002241311A (ja) * 2000-12-12 2002-08-28 Japan Tobacco Inc 界面活性剤を含む医薬組成物
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
EP1831352B1 (de) 2004-12-13 2011-07-13 CANJI, Inc. Zellinien zur produktion von replikationsdefektem adenovirus
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
JP5097714B2 (ja) 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
SI2007883T1 (sl) * 2006-04-20 2012-02-29 Wyeth Llc Procesi äśiĺ äśenja za osamitev preäśiĺ äśenega virusa vezikularnega stomatitisa iz celiäśne kulture
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EP3421603B1 (de) 2009-05-02 2021-10-06 Genzyme Corporation Gentherapie für neurodegenerative erkrankungen
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
SG190419A1 (en) 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX337348B (es) * 2011-04-29 2016-02-29 Oncolytics Biotech Inc Metodos para purificar virus utilizando cromatografia de permeacion en gel.
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN106459139A (zh) * 2014-05-28 2017-02-22 新加坡科技研究局 病毒减少方法
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EP3319634B1 (de) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2020264411A1 (en) * 2019-06-28 2020-12-30 Baxalta Incorporated Adeno-associated virus purification methods
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
CA2723040A1 (en) 1999-08-19
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
CN101164623B (zh) 2012-11-14
ATE371020T1 (de) 2007-09-15
ATE341614T1 (de) 2006-10-15
ES2290613T3 (es) 2008-02-16
IL137510A (en) 2012-10-31
PT1054955E (pt) 2007-01-31
CN100374551C (zh) 2008-03-12
CN101164623A (zh) 2008-04-23
IL137510A0 (en) 2001-07-24
DE69933433D1 (de) 2006-11-16
HUP0100670A3 (en) 2003-10-28
KR20010072547A (ko) 2001-07-31
NO20004104L (no) 2000-10-17
AR063314A2 (es) 2009-01-21
WO1999041416A2 (en) 1999-08-19
KR20090127947A (ko) 2009-12-14
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
KR100862169B1 (ko) 2008-10-09
SK11842000A3 (sk) 2001-05-10
EP1526174A3 (de) 2005-08-31
KR20080065614A (ko) 2008-07-14
JP2010213727A (ja) 2010-09-30
ATE478945T1 (de) 2010-09-15
ID28298A (id) 2001-05-10
KR100991683B1 (ko) 2010-11-04
TWI232107B (en) 2005-05-11
EP1526174A2 (de) 2005-04-27
DK1054955T3 (da) 2007-01-15
AU2653899A (en) 1999-08-30
DE69933433T2 (de) 2007-08-23
EP1526173A3 (de) 2005-08-10
JP2002503484A (ja) 2002-02-05
WO1999041416A3 (en) 1999-11-18
NO20004104D0 (no) 2000-08-16
HUP0100670A2 (hu) 2001-06-28
EP1741777B1 (de) 2010-08-25
EP1526173B1 (de) 2012-11-21
PL197747B1 (pl) 2008-04-30
CA2320419C (en) 2011-02-08
EP1054955B1 (de) 2006-10-04
DE69942708D1 (de) 2010-10-07
EP1526173A2 (de) 2005-04-27
HU226015B1 (en) 2008-02-28
MY141641A (en) 2010-05-31
AR063315A2 (es) 2009-01-21
KR100918187B1 (ko) 2009-09-22
JP4358434B2 (ja) 2009-11-04
DE69936948T2 (de) 2008-05-15
HK1097413A1 (en) 2007-06-22
KR100912362B1 (ko) 2009-08-19
AR020054A1 (es) 2002-04-10
HK1073481A1 (en) 2005-10-07
EP1526174B1 (de) 2007-08-22
AU757976B2 (en) 2003-03-13
KR20080065615A (ko) 2008-07-14
PE20000265A1 (es) 2000-04-25
ES2272053T3 (es) 2007-04-16
CN1297478A (zh) 2001-05-30
PL342847A1 (en) 2001-07-16
KR20090038927A (ko) 2009-04-21
KR101018992B1 (ko) 2011-03-07
BR9908015A (pt) 2001-04-24
CO4820440A1 (es) 1999-07-28
CA2320419A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
DE19882430T1 (de) Korrektur von Emissions-Kontamination und Totzeitverlust
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
DE69925333D1 (de) Zur richtigen Ausführung von Heft- und Lochungsoperationen geeignetes Bildformgerät
DE69925820D1 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
NO971495D0 (no) Svekkede virus og fremgangsmåte til deres fremstilling
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE69002558D1 (de) Zusammensetzungen und methoden zur verhinderung von inkrustierungen.
DE69821053D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidyl-Gruppen enthaltenden Polytriazinen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE59905059D1 (de) Verfahren zur Herstellung von Hydroxyethylcyclohexanen und Hydroxyethylpiperidinen
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
ATA4812000A (de) Mittel zur behandlung von hepatitis c
ATE255594T1 (de) Hepatitis b inhibitoren
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
DE69833655D1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition